Klinotab

Minocycline, the active ingredient in Klinotab, is a tetracycline antibiotic presented as an oral tablet for systemic use. It is employed to treat bacterial infections such as acne, skin and soft‑tissue infections, respiratory and urinary tract infections in adult patients.

GNH USA supplies Klinotab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required, and comprehensive regulatory support for importers.

Minocycline is indicated for several bacterial infection categories, targeting organisms that cause skin, respiratory, urinary and acne conditions.

Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the skin. Skin and soft‑tissue infections: eradicates susceptible Gram‑positive and Gram‑negative bacteria, promoting wound healing. Respiratory tract infections: treats community‑acquired pneumonia and bronchitis caused by susceptible strains. Urinary tract infections: eliminates common uropathogens, aiding resolution of cystitis and pyelonephritis.

Minocycline may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhoea - Photosensitivity - Dizziness - Headache

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Drug‑induced hepatitis - Severe vestibular toxicity (vertigo, ataxia) - Hypersensitivity reactions including anaphylaxis - Pseudotumor cerebri (intracranial hypertension)

Before prescribing Klinotab, clinicians should consider several safety factors. - Pregnancy: Category D – avoid unless the therapeutic benefit outweighs potential fetal risk. - Liver disease: use with caution; monitor hepatic function tests regularly. - Renal impairment: dose adjustment may be required; assess renal function before initiation. - Concomitant anticoagulants: monitor INR or clotting parameters for enhanced anticoagulant effect. - Children under 8 years: avoid due to risk of permanent tooth discoloration and enamel hypoplasia. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Minocycline can interact with other medicines, necessitating careful management.

Major Interactions (Avoid): - Isotretinoin – increased risk of intracranial hypertension. - Penicillins – antagonistic antibacterial effect, reducing overall efficacy. - Oral contraceptives – reduced hormonal efficacy, potentially leading to unintended pregnancy.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium – decrease minocycline absorption; separate dosing by at least 2 hours. - Warfarin – enhanced anticoagulant effect; monitor INR closely. - Phenytoin – increased hepatic metabolism of minocycline, potentially lowering therapeutic levels.